Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy.

Meta-analyses of randomized trials suggest a possible trend toward lower short-term mortality without a consistent functional benefit or thrombotic signal.

also in 939 other papers